Pasteurella Multocida Infection

Back

Background

Pasteurella multocida is a small, gram-negative, nonmotile, non–spore-forming coccobacillus with bipolar staining features.[1]  The bacteria typically appear as single bacilli on Gram stain; however, pairs and short chains also can be seen. P multocida often exists as a commensal in the upper respiratory tracts of many livestock, poultry, and domestic pet species, especially cats and dogs. In fact, Pasteurella species are some of the most prevalent commensal bacteria present in domestic and wild animals worldwide.[1, 2]  P multocida infection in humans often is associated with an animal bite, scratch, or lick, but infection without epidemiologic evidence of animal contact may occur.[1]  



View Image

Pasteurella multocida infection.

Wound infections associated with animal bites usually have a polymicrobial etiology, mandating the empiric use of broad-spectrum antimicrobials targeted at both aerobic and anaerobic gram-negative bacteria. Nevertheless, Pasteurella species commonly are isolated pathogens in most animal bites, especially in dog- and cat-related injuries. These injuries can be aggressive, with skin manifestations typically appearing within 24 hours after a bite. These wounds can exhibit a rapidly progressive soft-tissue inflammation that may resemble group A β-hemolytic Streptococcus pyogenes infections.

Deeper soft tissue also can be affected, manifesting as tenosynovitis, septic arthritis, and osteomyelitis. More-severe disseminating infections also may develop, including endocarditis or meningitis, the latter mimicking Haemophilus influenzae or Neisseria meningitides infections in young children. Fortunately, Pasteurella species are fairly sensitive organisms and can be treated with a penicillin-based regimen.[1]

Patients with P multocida infection who present without evidence of an animal bite are more likely to have invasive infection such as respiratory or bloodstream infection.[3]

Pathophysiology

Local:P multocida infection usually presents as an infection that complicates an animal bite or injury. Complications include rapidly progressive cellulitis, abscesses, tenosynovitis, osteomyelitis, and septic arthritis.[1, 4] The latter two are particularly common following cat bites because of their small, sharp, penetrative teeth.[5] Non-native septic arthritis also can occur.[6]

Respiratory:P multocida may cause upper respiratory tract infections, including sinusitis, otitis media, mastoiditis, epiglottitis,[7, 8]  pharyngitis, and Ludwig's angina.[9] In rare cases, P multocida also may cause lower respiratory tract infections, including pneumonia, tracheobronchitis, lung abscess,[10] and empyema,[11] usually in individuals with underlying pulmonary disease.[1]

Cardiovascular:P multocida has been reported to cause native-[12] and prosthetic-valve endocarditis,[13] pericarditis, mycotic aneurysms,[14] vascular graft infections,[15] central venous catheter infections, bacteremia, sepsis, septic shock,[16] and disseminated intravascular coagulation.[17]

Central nervous system:P multocida is an uncommon cause of meningitis,[18]  subdural empyema, and brain abscess.[19]  P multocida meningitis has been associated with cat licks and bites occurring on the face in persons at the extremes of age.[20]

Gastrointestinal:P multocida rarely causes gastrointestinal problems but has been associated with appendicitis, hepatosplenic abscesses, and spontaneous bacterial peritonitis. P multocida has been isolated in patients with polymicrobial peritoneal dialysis catheter–associated peritonitis.[21]

Ocular:P multocida periocular abscess,[22] conjunctivitis, corneal ulcers, and endophthalmitis have been reported.

Genitourinary tract:P multocida pyelonephritis, renal abscess, epididymitis, and cervicitis have been reported in rare cases.

Epidemiology

Frequency

United States

Transmission of infection from animals to humans typically occurs through bites, scratches, or other direct contact such as animal licking.[23] Annually, the United States reports approximately four to five million animal bite wounds, leading to about 300,000 emergency department visits. Bacteria are isolated from around 50% of dog-related wounds and 75% of cat-related wounds. Although dog bites are more frequent, the infection rate for dog bites is lower (3-18%) compared to cat bites (20-80%).

Infections can also occur indirectly, for example, through exposure to objects contaminated with animal saliva or dander, or by ingesting food that an animal has contacted. These infections can be severe and potentially life-threatening, particularly in individuals with comorbidities. Additionally, isolated cases of human wound infections have been documented from bites by a variety of other animals, including both wild and domestic species. P multocida is the most commonly cultured bacterium from these infected wounds, among other species such as P septica and P canis. The isolation and identification of these pathogens in clinical settings are typically not challenging.

International

P multocida infections occur worldwide. Cats are involved in 60-80% of human P multocida infections. Moreover, P multocida is isolated in 50% of dog bites.

Mortality/Morbidity

An estimated 10-20 human deaths per year occur following an animal bite.

Infectious complications occur in approximately 15-20% of dog-related bites and more than 50% of cat-related ones. After a bite, a rapidly progressive cellulitis may develop; deeper structures, including tendons, joints, and bones, can become affected, especially in cat-related injuries. Dissemination can occur.

Degenerative joint disease, rheumatoid arthritis, and prosthetic joints have been associated with the development of P multocida septic arthritis.[24]

Chronic obstructive pulmonary disease is a risk factor for P multocida respiratory tract infection,[25] which carries a mortality rate of approximately 30%. Diabetes mellitus[26] and liver dysfunction[27] are predisposing conditions associated with pasteurellosis and associated bacteremia.

P multocida infections during pregnancy and in utero transmission have also been reported.[28, 29, 30]

Localized P multocida infections carry an excellent prognosis. Significant morbidity has been associated with musculoskeletal P multocida infections, especially those involving the hand. Disseminated P multocida infections carry a 25-30% overall mortality risk.

Age

All age groups can be affected by P multocida infections. Young children seem to be frequently involved in nonfatal dog bites. P multocida meningitis typically occurs in persons at the extremes of age.

Prognosis

The outlook for P multocida infections generally is favorable, but the progression of the disease varies based on the location of the infection and the patient's existing health conditions.[1] Most infections involving soft tissue can be effectively treated with the right oral antibiotics and, if necessary, wound drainage. However, in more severe instances, such as cases involving bacteremia, meningitis, or endocarditis, the prognosis becomes much grimmer, with a significantly higher mortality rate of approximately 30%.

History

A history of exposure to animals, whether through work or leisure activities, should prompt physicians to consider the possibility of a zoonotic disease.[1] A comprehensive history of interactions with pets, including those owned by friends or strangers, may indicate a potential for Pasteurella infection. However, it is important to note that Pasteurella infections also can occur without any clear epidemiological link.

P multocida infections can affect any organ and system, and they are particularly concerning in elderly patients with chronic diseases who frequently come into contact with domestic animals, such as cats and dogs.[1] To prevent pasteurellosis, it is recommended to avoid animal bites, scratches, and direct contact with animal saliva. Thorough history-taking and microbiological confirmation are essential for accurately diagnosing and effectively treating the infection. Additionally, the increase in domestic and farm animal populations, driven by economic and societal growth and the expanding material and spiritual needs of humans, may elevate the risk for P multocida becoming a significant health concern that should not be underestimated.

Physical

Physical findings of P multocida infection relate to the site of infection, as follows[1] :

Causes

Causes of P multocida infection include the following[1] :

Approach Considerations

Pasteurella spp. should be considered as a potential cause of soft tissue infections following animal interactions such as bites, scratches, or licks from cats or dogs.[1] These infections are characterized by rapid onset and significant inflammatory responses, mirroring the clinical presentation seen with group A streptococcal infections caused by Streptococcus pyogenes. Notably, cat bites, due to their deep penetration, carry a heightened risk for serious complications including osteomyelitis, tenosynovitis, and septic arthritis, particularly in previously damaged joints or prosthetic joints. Individuals with compromised immune systems or underlying conditions such as liver failure, diabetes, malignancies, or severe infections like pneumonia, meningitis, or bacterial peritonitis are at increased risk for P multocida infections if exposed to animals.

Laboratory Studies

Diagnostically, P multocida can be identified from clinical specimens such as wound swabs, sputum, blood, cerebrospinal fluid, or synovial fluid through culture, PCR, or serological testing.[1] However, due to the antigenic variability of Pasteurellaceae and the limitations in taxonomic classification, serologic testing may yield false positives and is less definitive compared to viral serology. Culturing the organism on 5% Columbia Agar with sheep’s blood at 37 degrees Celsius in a 10% CO2 environment is the standard practice. Identification and antimicrobial susceptibility testing typically are conducted using automated systems like Vitek2, VITEK MS, Bruker Biotyper MS, alongside traditional biochemical tests. PCR remains a rapid, sensitive, and specific method for detecting P multocida and its subspecies, offering a reliable alternative to traditional biochemical testing methods.

Gram staining of purulent material or other fluid specimens, including blood, sputum, and cerebrospinal fluid, may reveal small, gram-negative, nonmotile, non–spore-forming pleomorphic coccobacilli, which are characteristic of P multocida.[1] However, organisms such as Haemophilus species, N meningitidis, Moraxella species, and Acinetobacter species share similar morphology and can be easily confused with Pasteurella species. Special stains like Wright, Giemsa, and Wayson enhance bipolar staining, and some P multocida strains may exhibit a mucous capsule. The definitive diagnosis is confirmed by identifying the organism in culture.

Pasteurella species are highly sensitive to several penicillins and cephalosporins.[1] Susceptibility testing is particularly indicated in immunocompromised patients and in cases of treatment failure or drug allergies, ensuring effective management of the infection.

 

 

 

 

 

Imaging Studies

CT scanning and/or MRI: Evaluation of tenosynovitis, septic arthritis, osteomyelitis, and meningeal enhancement, when appropriate

Echocardiography: Evaluation of suspected endocarditis

Procedures

Deep soft-tissue P multocida infections require debridement at times. Intraoperative cultures should be taken at time of surgery.

Lumbar puncture should be performed if meningitis is suspected.

Arthrocentesis should be performed if septic arthritis is suspected.

Abdominal paracentesis is required in patients with ascites to assess the possibility of spontaneous bacterial peritonitis, especially in those with significant clinical liver disease with a history of pet exposure.

Histologic Findings

When available, infected tissue has features consistent with an acute purulent inflammation with neutrophilic predominance and possibly necrosis.

Approach Considerations

Animal bite wounds require immediate medical intervention, including thorough disinfection and surgical debridement to remove debris, abscesses, and necrotic tissue.[1, 31] Prompt initiation of antibiotic therapy is essential. If the wound is located on a limb, elevating it can help reduce swelling. For local Pasteurella multocida infections, penicillin or its derivatives, such as oral amoxicillin-clavulanate, are generally effective, even in the absence of culture confirmation. However, resistance to penicillin, evidenced by β-lactamase positivity, has been reported in 16% of cases. Alternative antibiotic therapies with proven anti-Pasteurella activity include doxycycline, trimethoprim/sulfamethoxazole, penicillin V, cefuroxime, ciprofloxacin, or levofloxacin, often combined with an anti-anaerobic agent like metronidazole or clindamycin to address other components of the oral flora.

For systemic infections involving P multocida, where cultures from blood, deep tissues, or the respiratory tract are positive, aggressive antibiotic treatment is warranted.[1, 31] First-line parenteral options include monotherapy with ampicillin-sulbactam, piperacillin-tazobactam, or a carbapenem such as imipenem-cilastatin, meropenem, or ertapenem. Alternatives include ceftriaxone or a fluoroquinolone paired with an anti-anaerobic agent. It is important to note that certain antibiotics, including oral erythromycin, semi-synthetic penicillins, first-generation cephalosporins, and clindamycin, have shown poor in vitro activity against P multocida and are not recommended for treatment. Resistance to penicillin G, ampicillin, and tetracycline has been particularly noted in chronic pulmonary infections. Antibiotic regimens should be specifically tailored based on culture results and sensitivity testing. Treatment typically lasts between 5 to 14 days, but may need to be extended in cases of severe infection or slow clinical response.

Medical Care

Because P multocida infection mostly is encountered in the setting of an injury following an animal bite, physicians must be familiar with the associated microbiological oral flora of certain animals, especially dogs and cats.[1, 31]

Most animal bites are polymicrobial, with both aerobic and anaerobic bacteria. Several species can be isolated at once.

Several Pasteurella species are associated with dog and cat bites, including P multocida subspecies multocida,P multocida subspecies septica, Pasteurella stomatis, and Pasteurelladogmatis. Pasteurella canis is associated only with dog bites.

Other fastidious gram-negative organisms that have been associated with dog and cat bites include Capnocytophaga canimorsus and Capnocytophaga cynodegmi, especially in patients who had undergone previous splenectomy. C canimorsus infection can cause fulminant sepsis and meningitis, whereas C cynodegmi infection usually causes a milder localized inflammation.

Several other organisms are associated with cat bites, including Bartonella henselae, Francisella tularensis, and cowpox virus.

Medical management of animal bite wounds includes local wound care, standard-protocol tetanus prophylaxis, standard-protocol rabies prophylaxis, and either oral or intravenous empiric antimicrobial treatment.

Please see Medication for more detail about antimicrobial treatment.

Local care of bite wounds includes cleansing and removing nonviable tissue. Gently cleanse the skin surrounding the bite wound with an antiseptic solution. To prevent further tissue injury, do not scrub the wound directly. Soaking is of no benefit, but copious irrigation with a small-gauge catheter on a syringe helps remove debris and decreases the concentration of bacteria in contaminated wounds.

Please see Surgical Care for more detail about debridement and closure.

Surgical Care

The initial assessment of an animal bite includes an estimation of the infection risk.[1, 31] Bites to the head and neck, to the distal extremities, and near joints carry the highest risk for infection. In general, persons with animal bite wounds are at a high risk for infection, especially those who present to medical attention more than 8-10 hours after the injury occurred.

Persons with underlying medical diseases, such as diabetes mellitus, chronic liver disease, asplenia, alcoholism, HIV infection, or other immunodeficiency conditions (including chronic steroid exposure), are at increased risk for infection.

After irrigation and cleansing, sharply debride nonviable tissue to reduce the risk for infection and to allow easier suturing by providing a more even edge.

Primary suturing of bite wounds is reserved for minor injuries, those at low risk for infection, and those that have been treated within 8-10 hours of injury.

Leave all other wounds open until the risk for infection is reduced by cleansing, debridement, and prophylactic antibiotics.

Consultations

Consultations include the following:

Activity

Elevation is of great importance in the management of limb injuries. Lack of elevation may result in excessive edema, which may produce compartment syndrome and compromise local circulation, to the extent of threatening the viability of the limb.[1, 31]

Wounds on extremities should be immobilized and elevated with a sling to reduce edema, which may hamper normal activities.

Medication Summary

Antimicrobial resistance among Pasteurella isolates rarely is reported in humans.[1, 31] Erythromycin, cephalexin and clindamycin most commonly are associated with resistance. Penicillin-resistance is rare; resistant strains have been isolated only from respiratory tract infections. Most animal-bite injuries can be treated with oral antimicrobials on an outpatient basis. Severe or partially responding infections may necessitate hospitalization and parenteral antimicrobial administration, along with surgical intervention.[1]

Most Pasteurella isolates are susceptible to oral antimicrobials such as amoxicillin, amoxicillin/clavulanic acid, tetracyclines, fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin), and trimethoprim-sulfamethoxazole. Based on in vitro susceptibility data, several antimicrobials should not be used empirically for P multocida infections, including dicloxacillin, vancomycin, cephalexin, cefaclor, cefadroxil, erythromycin, and clindamycin. Macrolide resistance usually is encountered with erythromycin. Other macrolides, including azithromycin, clarithromycin, and telithromycin (in order of decreasing susceptibility), retain in vitro activity against most Pasteurella strains. Aminoglycosides have poor activity against P multocida.

More severe infections may require parenteral antibiotics. Intravenous ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin-tazobactam, cefoxitin, and carbapenems (imipenem-cilastatin, meropenem, ertapenem) are excellent empiric options for animal-bite injuries, providing gram-positive, gram-negative, and anaerobic coverage. The tetracycline-derivative tigecycline also has excellent in vitro activity against P multocida and other pathogens encountered in animal and bite injuries. If P multocida is the only isolated organism, therapy may be changed to intravenous penicillin G. Once clinical improvement is noted, oral penicillin VK is an option. Patients with penicillin allergies can receive minocycline, doxycycline, fluoroquinolones, trimethoprim-sulfamethoxazole, or azithromycin.

The duration of therapy for P multocida infection has not been well established and can be tailored to clinical response. Milder soft-tissue infections usually require 7-10 days of oral therapy. More severe cases can be treated for 10-14 days. Deep-tissue infections often require 4-6 weeks of treatment, and intravenous therapy may be indicated initially.

Amoxicillin and clavulanate (Augmentin)

Clinical Context:  Drug combination treats bacteria resistant to beta-lactam antibiotics. For children >3 mo, base dosing protocol on amoxicillin content. Because of different ratios of amoxicillin to clavulanic acid in 250-mg tab (250:125) vs 250-mg chewable tab (250:62.5), do not use 250-mg tab until child weighs >40 kg.

Cefuroxime (Ceftin, Zinacef)

Clinical Context:  Second-generation cephalosporin that maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration.

Doxycycline (Vibra-Tabs, Bio-Tab, Doryx, Vibramycin)

Clinical Context:  Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Penicillin G (Pfizerpen)

Clinical Context:  Inhibits biosynthesis of cell wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations are reached. Most effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. Use penicillin VK for PO or penicillin G for IV.

Ampicillin and sulbactam (Unasyn)

Clinical Context:  Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens.

Ticarcillin and clavulanate (Timentin)

Clinical Context:  Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes.

Ciprofloxacin (Cipro)

Clinical Context:  Mode of action of all quinolones involves inhibition of bacterial DNA synthesis by blocking the enzyme DNA gyrase

Amoxicillin (Trimox, Amoxil)

Clinical Context:  Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria.

Levofloxacin (Levaquin)

Clinical Context:  For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms.

Ampicillin (Principen, Omnipen)

Clinical Context:  Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication PO.

Piperacillin and tazobactam sodium (Zosyn)

Clinical Context:  Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication.

Ertapenem (Invanz)

Clinical Context:  Bactericidal activity results from inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin-binding proteins. Stable against hydrolysis by various beta-lactamases including penicillinases, cephalosporinases, and extended-spectrum beta-lactamases. Hydrolyzed by metallo-beta-lactamases.

Imipenem and cilastatin (Primaxin)

Clinical Context:  For treatment of multi-organism infections in which other agents do not have wide-spectrum coverage or are contraindicated because of potential for toxicity.

Minocycline (Dynacin, Minocin)

Clinical Context:  Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma species.

Cefoxitin (Mefoxin)

Clinical Context:  Second-generation cephalosporin with activity against some gram-positive cocci, gram-negative rod infections, and anaerobic bacteria. Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits final transpeptidation step of peptidoglycan synthesis, resulting in cell wall death.

Infections caused by cephalosporin- or penicillin-resistant gram-negative bacteria may respond to cefoxitin.

Sulfamethoxazole and trimethoprim (Bactrim, Bactrim DS, Septra, Septra DS)

Clinical Context:  Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

Antibacterial activity of TMP-SMZ includes common urinary tract pathogens, except Pseudomonas aeruginosa.

Azithromycin (Zithromax)

Clinical Context:  Acts by binding to 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected.

Concentrates in phagocytes and fibroblasts as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.

Treats mild-to-moderate microbial infections.

Tigecycline (Tygacil)

Clinical Context:  A glycylcycline antibiotic that is structurally similar to tetracycline antibiotics. Inhibits bacterial protein translation by binding to 30S ribosomal subunit and blocks entry of amino-acyl tRNA molecules in ribosome A site. Complicated intra-abdominal infections caused by C freundii, E cloacae, E coli, K oxytoca, K pneumoniae, E faecalis (vancomycin-susceptible isolates only), S aureus (methicillin-susceptible isolates only), S anginosus group (includes S anginosus, S intermedius, and S constellatus), B fragilis, B thetaiotaomicron, B uniformis, B vulgatus, C perfringens, and P micros.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Further Outpatient Care

Careful follow-up evaluations of extensive bites or deep puncture wounds from cat bites are mandatory for early diagnosis of tenosynovitis, septic arthritis, and osteomyelitis.

Complications

Abscesses and tenosynovitis are the most common complications of P multocida soft-tissue infection. Septic arthritis and osteomyelitis are less common. CNS involvement with meningitis can occur. Dissemination is rare.

Prognosis

Soft-tissue P multocida infections carry an excellent prognosis. Deeper wounds, especially hand infections, may be associated with prolonged morbidity.

P multocida pulmonary infections, CNS involvement, bacteremia, and endocarditis carry a mortality rate of approximately 30%. Recent data show that patients presenting without evidence of an animal bite more frequently had respiratory and bloodstream infections and were relatively immunocompromised at baseline. These patients had a worse prognosis than patients with evidence of animal bite on presentation.[3]

What is Pasteurella multocida infection?What is the pathophysiology of Pasteurella multocida infection?What is the incidence of Pasteurella multocida infection in the US?What is the global incidence of Pasteurella multocida infection?What is the mortality from of Pasteurella multocida infection?What are possible complications of Pasteurella multocida infection?What is the prognosis of Pasteurella multocida infection?How does the incidence of Pasteurella multocida infection vary by age?What should be the focus of clinical history in evaluation for Pasteurella multocida infection?Which physical findings are characteristic of Pasteurella multocida infection?What are the causes of Pasteurella multocida infection?What are the differential diagnoses for Pasteurella Multocida Infection?What is the role of lab studies in the workup of Pasteurella multocida infection?What is the role of imaging studies in the workup of Pasteurella multocida infection?Which procedures are performed in the workup of Pasteurella multocida infection?Which histologic findings are characteristic of Pasteurella multocida infection?Which bacteria species are associated with Pasteurella multocida infection?What is included in the medical management for Pasteurella multocida infection?What is the role of surgery in the treatment of Pasteurella multocida infection?Which medical personnel may provide consultation to patients with Pasteurella multocida infection?Which activity modifications are used in the treatment of Pasteurella multocida infection?What is the efficacy of medications used in the treatment of Pasteurella multocida infection?Which medications in the drug class Antibiotics are used in the treatment of Pasteurella Multocida Infection?When is follow-up care needed for patients with Pasteurella multocida infection?What are the complications of Pasteurella multocida infection?What is the prognosis of Pasteurella multocida infection?Where can patient education resources about Pasteurella multocida infection be found?

Author

Sara L Cross, MD, Assistant Professor, Department of Internal Medicine, Division of Infectious Diseases, Assistant Professor, Department of Medical Education, University of Tennessee Health Science Center College of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Michael Gelfand, MD, FACP, Chief, Professor, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis, University of Tennessee Health Science Center College of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron E Glatt, MD, MACP, FIDSA, FSHEA, Chairman, Department of Medicine, Chief, Division of Infectious Diseases, Hospital Epidemiologist, Mount Sinai South Nassau; Professor of Medicine, Icahn School of Medicine at Mount Sinai

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Larry I Lutwick, MD, FACP, Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

J Robert Cantey, MD Professor, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina

J Robert Cantey, MD is a member of the following medical societies: Alpha Omega Alpha, American Society for Clinical Investigation, American Society for Microbiology, Infectious Diseases Society of America, International Society of Travel Medicine, Musculoskeletal Infection Society, Phi Beta Kappa, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Alexandre Lacasse, MD, MSc Internal Medicine Faculty, Assistant Director, Medicine Clinic, Infectious Disease Consultant, St Mary's Health Center

Alexandre Lacasse, MD, MSc is a member of the following medical societies: American College of Physicians, American Medical Association, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose. Thomas Lafeber, MD Consulting Staff, Wellstar Infectious Disease LLC

Thomas Lafeber, MD is a member of the following medical societies: American Medical Association, American Society of Transplantation, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References

  1. Piorunek M, Brajer-Luftmann B, Walkowiak J. Pasteurella Multocida Infection in Humans. Pathogens. 2023 Oct 1. 12 (10):[View Abstract]
  2. Wilkie IW, Harper M, Boyce JD, Adler B. Pasteurella multocida: diseases and pathogenesis. Curr Top Microbiol Immunol. 2012. 361:1-22. [View Abstract]
  3. Giordano A, Dincman T, Clyburn BE, Steed LL, Rockey DC. Clinical Features and Outcomes of Pasteurella multocida Infection. Medicine (Baltimore). 2015 Sep. 94 (36):e1285. [View Abstract]
  4. Heydemann J, Heydemann JS, Antony S. Acute infection of a total knee arthroplasty caused by Pasteurella multocida: a case report and a comprehensive review of the literature in the last 10 years. Int J Infect Dis. 2010 Sep. 14 Suppl 3:e242-5. [View Abstract]
  5. Oehler RL, Velez AP, Mizrachi M, Lamarche J, Gompf S. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis. 2009 Jul. 9(7):439-47. [View Abstract]
  6. Lam PW, Page AV. Pasteurella multocida non-native joint infection after a dog lick: A case report describing a complicated two-stage revision and a comprehensive review of the literature. Can J Infect Dis Med Microbiol. 2015 Jul-Aug. 26 (4):212-7. [View Abstract]
  7. Jan L, Boute P, Mouawad F. Pasteurella multocida acute epiglottitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2021 Mar. 138 (2):100-102. [View Abstract]
  8. Harris PJ, Osswald MB. Pasteurella multocida epiglottitis: A review and report of a new case with associated chronic lymphocytic leukemia. Ear Nose Throat J. 2010 Dec. 89(12):E4. [View Abstract]
  9. Dryden MS, Dalgliesh D. Pasteurella multocida from a dog causing Ludwig's angina. Lancet. 1996 Jan 13. 347(8994):123. [View Abstract]
  10. Goussard P, Gie RP, Steyn F, Rossouw GJ, Kling S. Pasteurella multocida lung and liver abscess in an immune-competent child. Pediatr Pulmonol. 2006 Mar. 41(3):275-8. [View Abstract]
  11. Kagihara JM, Brahmbhatt NM, Paladino J. A fatal pasteurella empyema. Lancet. 2014 Aug 2. 384(9941):468. [View Abstract]
  12. Mikaberidz N, Li EY, Taub CC. Pasteurella multocida infective endocarditis in an immunocompetent patient complicated by rhabdomyolysis and permanent hearing loss. J Cardiovasc Dis Res. 2013 Mar. 4(1):55-7. [View Abstract]
  13. Nettles RE, Sexton DJ. Pasteurella multocida prosthetic valve endocarditis: case report and review. Clin Infect Dis. 1997 Oct. 25(4):920-1. [View Abstract]
  14. Koelemay MJ. Pasteurella multocida infection, a rare cause of mycotic abdominal aortic aneurysm. J Vasc Surg. 2009 Dec. 50(6):1496-8. [View Abstract]
  15. Schneider JR, White GW, Dejesus EF. Pasteurella multocida-infected expanded polytetrafluoroethylene hemodialysis access graft. Ann Vasc Surg. 2012 Nov. 26(8):1128.e15-7. [View Abstract]
  16. Adler AC, Cestero C, Brown RB. Septic shock from Pasturella multocida following a cat bite: case report and review of literature. Conn Med. 2011 Nov-Dec. 75(10):603-5. [View Abstract]
  17. Fukuchi T, Morisawa Y. [A case of cat-scratch-induced Pasteurella multocida infection presenting with disseminated intravascular coagulation and acute renal failure]. Kansenshogaku Zasshi. 2009 Sep. 83(5):557-60. [View Abstract]
  18. Green BT, Ramsey KM, Nolan PE. Pasteurella multocida meningitis: case report and review of the last 11 y. Scand J Infect Dis. 2002. 34(3):213-7. [View Abstract]
  19. Per H, Kumandas S, Gümüs H, Oztürk MK, Coskun A. Meningitis and subgaleal, subdural, epidural empyema due to Pasteurella multocida. J Emerg Med. 2010 Jul. 39(1):35-8. [View Abstract]
  20. Wade T, Booy R, Teare EL, et al. Pasteurella multocida meningitis in infancy - (a lick may be as bad as a bite). Eur J Pediatr. 1999 Nov. 158(11):875-8. [View Abstract]
  21. Antony SJ, Oglesby KA. Peritonitis associated with Pasteurella multocida in peritoneal dialysis patients--case report and review of the literature. Clin Nephrol. 2007 Jul. 68(1):52-6. [View Abstract]
  22. Hutcheson KA, Magbalon M. Periocular abscess and cellulitis from Pasteurella multocida in a healthy child. Am J Ophthalmol. 1999 Oct. 128(4):514-5. [View Abstract]
  23. Smallman TR, Perlaza-Jiménez L, Wang X, Korman TM, Kotsanas D, Gibson JS, et al. Pathogenomic analysis and characterization of Pasteurella multocida strains recovered from human infections. Microbiol Spectr. 2024 Apr 2. 12 (4):e0380523. [View Abstract]
  24. Blanco JF, Pescador D, Martín JM, Cano C, Sánchez MD. Acute infection of total knee arthroplasty due to a cat scratch in a patient with rheumatoid arthritis. J Clin Rheumatol. 2012 Sep. 18(6):314-5. [View Abstract]
  25. Myers EM, Ward SL, Myers JP. Life-threatening respiratory pasteurellosis associated with palliative pet care. Clin Infect Dis. 2012 Mar. 54(6):e55-7. [View Abstract]
  26. Tattevin P, Souala F, Gautier AL, et al. Diabetes in patients with pasteurellosis. Scand J Infect Dis. 2005. 37(10):731-3. [View Abstract]
  27. Brivet F, Guibert M, Barthelemy P, et al. Pasteurella multocida sepsis after hemorrhagic shock in a cirrhotic patient: possible role of endoscopic procedures and gastrointestinal translocation. Clin Infect Dis. 1994 May. 18(5):842-3. [View Abstract]
  28. Rollof J, Johansson PJ, Holst E. Severe Pasteurella multocida infections in pregnant women. Scand J Infect Dis. 1992. 24(4):453-6. [View Abstract]
  29. Waldor M, Roberts D, Kazanjian P. In utero infection due to Pasteurella multocida in the first trimester of pregnancy: case report and review. Clin Infect Dis. 1992 Feb. 14(2):497-500. [View Abstract]
  30. Waghorn DJ, Robson M. Occupational risk of Pasteurella multocida septicaemia and premature labour in a pregnant vet. BJOG. 2003 Aug. 110(8):780-1. [View Abstract]
  31. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [View Abstract]
  32. Baud D, Bizzini A, Jaton K, Achtari C, Prod'hom G, Greub G. Pasteurella multocida Zoonotic Ascending Infection: An Unusual Cause of Tubo-Ovarian Abscess. Vector Borne Zoonotic Dis. 2011 Sep 16. [View Abstract]
  33. American Academy of Pediatrics. Bite Wounds. Red Book 2012 - Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2012. 203-6.
  34. Champlin FR, Shryock TR, Patterson CE, et al. Prevalence of a novel capsule-associated lipoprotein among pasteurellaceae pathogenic in animals. Curr Microbiol. 2002 Apr. 44(4):297-301. [View Abstract]
  35. Chang K, Siu LK, Chen YH, et al. Fatal Pasteurella multocida septicemia and necrotizing fasciitis related with wound licked by a domestic dog. Scand J Infect Dis. 2007. 39(2):167-70. [View Abstract]
  36. Citron DM, Warren YA, Fernandez HT, et al. Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species isolated from human clinical specimens. J Clin Microbiol. 2005 May. 43(5):2485-8. [View Abstract]
  37. Clark RB, Joyce SE. Activity of meropenem and other antimicrobial agents against uncommon gram-negative organisms. J Antimicrob Chemother. 1993 Aug. 32(2):233-7. [View Abstract]
  38. Fajfar-Whetstone CJ, Coleman L, Biggs DR, Fox BC. Pasteurella multocida septicemia and subsequent Pasteurella dagmatis septicemia in a diabetic patient. J Clin Microbiol. 1995 Jan. 33(1):202-4. [View Abstract]
  39. Goldstein EJ, Citron DM. Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds. Antimicrob Agents Chemother. 1988 Aug. 32(8):1143-8. [View Abstract]
  40. Goldstein EJ, Citron DM, Merriam CV, et al. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother. 1999 Jun. 43(6):1475-9. [View Abstract]
  41. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother. 2000 Oct. 44(10):2747-51. [View Abstract]
  42. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother. 2002 Sep. 50(3):411-20. [View Abstract]
  43. Goldstein EJ, Citron DM, Richwald GA. Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida. Antimicrob Agents Chemother. 1988 Feb. 32(2):213-5. [View Abstract]
  44. Griego RD, Rosen T, Orengo IF, et al. Dog, cat, and human bites: a review. J Am Acad Dermatol. 1995 Dec. 33(6):1019-29. [View Abstract]
  45. Hey P, Gow P, Torresi J, Testro A. Cirrhosis, cellulitis and cats: a 'purrfect' combination for life-threatening spontaneous bacterial peritonitis from Pasteurella multocida. BMJ Case Rep. 2012 Nov 11. 2012:[View Abstract]
  46. Kimura R, Hayashi Y, Takeuchi T, et al. Pasteurella multocida septicemia caused by close contact with a domestic cat: case report and literature review. J Infect Chemother. 2004 Aug. 10(4):250-2. [View Abstract]
  47. Kravetz JD, Federman DG. Cat-associated zoonoses. Arch Intern Med. 2002 Sep 23. 162(17):1945-52. [View Abstract]
  48. Lion C, Conroy MC, Carpentier AM, et al. Antimicrobial susceptibilities of Pasteurella strains isolated from humans. Int J Antimicrob Agents. 2006 Apr. 27(4):290-3. [View Abstract]
  49. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000. 2404-7.
  50. Murphy E. Microbiology of animal bites. Clinical Microbiology Newsletter. Apr 2008. 30(7):47-50.
  51. Raval P, Khan W, Haddad B, Mahapatra AN. Bite injuries to the hand - review of the literature. Open Orthop J. 2014. 8:204-8. [View Abstract]
  52. Rosenau A, Labigne A, Escande F, et al. Plasmid-mediated ROB-1 beta-lactamase in Pasteurella multocida from a human specimen. Antimicrob Agents Chemother. 1991 Nov. 35(11):2419-22. [View Abstract]
  53. Weber DJ, Wolfson JS, Swartz MN, et al. Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore). 1984 May. 63(3):133-54. [View Abstract]

Pasteurella multocida infection.

Pasteurella multocida infection.